Yasuo Hamamoto

11.0k total citations · 4 hit papers
155 papers, 5.8k citations indexed

About

Yasuo Hamamoto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Yasuo Hamamoto has authored 155 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Oncology, 86 papers in Pulmonary and Respiratory Medicine and 65 papers in Surgery. Recurrent topics in Yasuo Hamamoto's work include Gastric Cancer Management and Outcomes (63 papers), Esophageal Cancer Research and Treatment (42 papers) and Colorectal Cancer Treatments and Studies (41 papers). Yasuo Hamamoto is often cited by papers focused on Gastric Cancer Management and Outcomes (63 papers), Esophageal Cancer Research and Treatment (42 papers) and Colorectal Cancer Treatments and Studies (41 papers). Yasuo Hamamoto collaborates with scholars based in Japan, United States and South Korea. Yasuo Hamamoto's co-authors include Yasushi Sano, Hirohisa Machida, Shigeaki Yoshida, Takao Endo, Ken Kato, Yuko Kitagawa, Takashi Obi, Masahiro Yamaguchi, Kazuhiro Gono and Nagaaki Ohyama and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Surgery and Scientific Reports.

In The Last Decade

Yasuo Hamamoto

149 papers receiving 5.6k citations

Hit Papers

Nivolumab versus chemother... 2004 2026 2011 2018 2019 2004 2013 2017 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
    2019 751 citations Ken Kato, Keisho Chìn et al. profile →
  2. Appearance of enhanced tissue features in narrow-band endoscopic imaging
    2004 688 citations Yasushi Sano, Shigeaki Yoshida et al. profile →
  3. Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial
    2013 351 citations Shuichi Hironaka, Hirofumi Yasui et al. Journal of Clinical Oncology profile →
  4. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
    2017 292 citations Toshihiro Kudo, Yasuo Hamamoto et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yasuo Hamamoto Japan 33 3.3k 3.0k 2.9k 738 546 155 5.8k
Alexander Meining Germany 41 3.0k 0.9× 3.9k 1.3× 2.3k 0.8× 879 1.2× 265 0.5× 151 5.4k
Shigeaki Yoshida Japan 39 5.5k 1.6× 4.3k 1.4× 2.2k 0.8× 1.6k 2.2× 437 0.8× 122 7.2k
Amitabh Srivastava United States 38 2.2k 0.7× 1.8k 0.6× 2.6k 0.9× 492 0.7× 445 0.8× 123 4.7k
Yutaka Yonemura Japan 48 2.8k 0.9× 5.7k 1.9× 1.7k 0.6× 1.3k 1.8× 993 1.8× 294 8.4k
Jyothi P. Jagannathan United States 37 2.2k 0.7× 1.1k 0.4× 1.8k 0.6× 394 0.5× 605 1.1× 141 4.7k
Manoop S. Bhutani United States 48 4.2k 1.3× 5.1k 1.7× 3.8k 1.3× 1.2k 1.6× 481 0.9× 375 8.0k
William Kraybill United States 35 1.9k 0.6× 1.3k 0.4× 2.9k 1.0× 416 0.6× 742 1.4× 94 4.6k
Frank P. Vleggaar Netherlands 42 3.7k 1.1× 4.6k 1.5× 2.1k 0.7× 409 0.6× 399 0.7× 160 7.0k
Johannes J. Bonenkamp Netherlands 28 4.0k 1.2× 2.2k 0.7× 1.2k 0.4× 2.2k 2.9× 499 0.9× 65 5.7k
Krish Ragunath United Kingdom 45 4.2k 1.3× 5.1k 1.7× 1.6k 0.6× 1.6k 2.1× 393 0.7× 204 7.0k

Countries citing papers authored by Yasuo Hamamoto

Since Specialization
Citations

This map shows the geographic impact of Yasuo Hamamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasuo Hamamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasuo Hamamoto more than expected).

Fields of papers citing papers by Yasuo Hamamoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasuo Hamamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasuo Hamamoto. The network helps show where Yasuo Hamamoto may publish in the future.

Co-authorship network of co-authors of Yasuo Hamamoto

This figure shows the co-authorship network connecting the top 25 collaborators of Yasuo Hamamoto. A scholar is included among the top collaborators of Yasuo Hamamoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasuo Hamamoto. Yasuo Hamamoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yamamoto, Shun, Satoru Matsuda, Takahiro Tsushima, et al.. (2025). Phase II study of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel for resectable esophageal squamous cell carcinoma.. Journal of Clinical Oncology. 43(4_suppl). 418–418.
2.
Kawasaki, Kenta, Hideyuki Hayashi, S. Shimizu, et al.. (2024). Clinical characteristics of gastrointestinal stromal tumors with hypoglycemia. Oncology Letters. 28(6). 568–568. 1 indexed citations
3.
Kawazoe, Akihito, Kensei Yamaguchi, Tsuyoshi Hamaguchi, et al.. (2023). 1546P Safety, efficacy, and biomarkers for ONO-4578 plus nivolumab in unresectable advanced or recurrent gastric or gastroesophageal cancer. Annals of Oncology. 34. S867–S867. 1 indexed citations
4.
Hamamoto, Yasuo, Kentaro Murakami, Ken Kato, & Yuko Kitagawa. (2022). Management of elderly patients with esophageal squamous cell cancer. Japanese Journal of Clinical Oncology. 52(8). 816–824. 9 indexed citations
5.
Shimozaki, Keitaro, Yasutaka Sukawa, Yasunori Sato, et al.. (2021). Analysis of Risk Factors for Immune-Related Adverse Events in Various Solid Tumors Using Real-World Data. Future Oncology. 17(20). 2593–2603. 16 indexed citations
6.
Shimozaki, Keitaro, Kenro Hirata, Yukie Hayashi, et al.. (2021). The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study. Diagnostics. 11(3). 543–543. 2 indexed citations
7.
Kato, Ken, Yuichiro� Doki, Takashi Ura, et al.. (2020). Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. Cancer Science. 111(5). 1676–1684. 23 indexed citations
8.
Takeuchi, Masashi, Chiyo K. Imamura, Eisuke Booka, et al.. (2020). Prospective evaluation and refinement of an S‐1 dosage formula based on renal function for clinical application. Cancer Science. 112(2). 751–759. 3 indexed citations
9.
Hayashi, Yukie, Naoki Hosoe, Kaoru Takabayashi, et al.. (2020). Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis. Digestive Diseases and Sciences. 66(6). 2129–2134. 28 indexed citations
10.
11.
Hamamoto, Yasuo, Naoki Sakakibara, Fumio Nagashima, Yuko Kitagawa, & Takahiro Higashi. (2018). Treatment selection for esophageal cancer: evaluation from a nationwide database. Esophagus. 15(2). 109–114. 9 indexed citations
12.
Takeuchi, Masashi, Koichi Suda, Yasuo Hamamoto, et al.. (2018). Technical feasibility and oncologic safety of diagnostic endoscopic resection for superficial esophageal cancer. Gastrointestinal Endoscopy. 88(3). 456–465. 18 indexed citations
13.
Saito, Mayuko, Kentaro Yamashita, Yoshiaki Arimura, et al.. (2016). Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK). Acta Oncologica. 55(3). 309–317. 9 indexed citations
14.
Satoh, Taroh, Yung‐Jue Bang, Evgeny Gotovkin, et al.. (2014). Quality of Life in the Trastuzumab for Gastric Cancer Trial. The Oncologist. 19(7). 712–719. 36 indexed citations
15.
Morizane, Chigusa, Takuji Okusaka, Junki Mizusawa, et al.. (2013). Randomized phase II study of gemcitabine plus S‐1 versus S‐1 in advanced biliary tract cancer: A Japan Clinical Oncology Group trial (JCOG 0805). Cancer Science. 104(9). 1211–1216. 80 indexed citations
16.
Nishi, Tomohiro, et al.. (2012). [A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy].. PubMed. 39(13). 2553–5. 2 indexed citations
17.
18.
Yamaguchi, Kensei, Akira Sawaki, Toshihiko Doi, et al.. (2012). Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study. Gastric Cancer. 16(2). 175–182. 20 indexed citations
19.
Sano, Yasushi, Masahiko Kobayashi, Yasuo Hamamoto, et al.. (2001). New diagnostic method based on color imaging using narrow band imaging (NBI) system for gastrointestinal tract. Gastrointestinal Endoscopy. 53(5). AB125–AB125. 70 indexed citations
20.
Saitoh, Hiroki, Narikazu Boku, Atsushi Ohtsu, et al.. (2000). Five-year survivor with liver metastasis from gastric cancer successfully treated with systemic chemotherapy. Gastric Cancer. 3(2). 106–109. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander Meining Breakdown of academic impact, for papers by Shigeaki Yoshida Breakdown of academic impact, for papers by Amitabh Srivastava Breakdown of academic impact, for papers by Yutaka Yonemura Breakdown of academic impact, for papers by Jyothi P. Jagannathan Breakdown of academic impact, for papers by Manoop S. Bhutani Breakdown of academic impact, for papers by William Kraybill Breakdown of academic impact, for papers by Frank P. Vleggaar Breakdown of academic impact, for papers by Johannes J. Bonenkamp Breakdown of academic impact, for papers by Krish Ragunath
Rankless by CCL
2026